AVTX

Avalo Therapeutics, Inc. is a biotechnology company listed in the healthcare sector with a market capitalization of $290.69M. The company has 23 employees and operates within the biotechnology industry. The financial health of Avalo Therapeutics is marked by significant losses, with net income totaling -$99,701,000 over the trailing twelve months. Margins are negative across all categories, including gross margin at 0.0%, operating margin at -34632.3%, and profit margin at 0.0%. The company's returns on equity and assets are also negative, standing at -174.8% and -37.2%, respectively. On the balance sheet, Avalo Therapeutics has $555,000 in debt and $111.62M in cash, resulting in a debt to equity ratio of 0.61. Avalo Therapeutics' valuation metrics are notable, with a price to sales ratio of 1514.00, indicating significant premium to revenue. The forward P/E ratio is -3.52, suggesting a possible reversal or adjustment in investor sentiment. The company's cash and debt levels will be a key factor in future growth prospects, which are currently not available due to the N/A designation for revenue and earnings growth rates.